Gene Therapy Market Size and Growth Analysis by Type (In vivo, Ex vivo), Vector Type (Viral, Non-Viral), Application (Oncology, Rare Diseases, Neurology, Ophthalmology, Hematology, Infectious Diseases, Cardiology), End User (Pharmaceutical and Biotechnology Companies, Academic Institutes and Research Centers) - Global Industry Demand Forecast to 2030

Chapter 1. Research Scope

1.1. Research Objectives

1.2. Market Definition

1.3. Analysis Period

1.4. Market Size Breakdown by Segment

1.4.1. Market size breakdown, by type

1.4.2. Market size breakdown, by vector type

1.4.3. Market size breakdown, by application

1.4.4. Market size breakdown, by end user

1.4.5. Market size breakdown, by region

1.5. Market Data Reporting Unit

1.5.1. Value

1.6. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research

2.1.1. Paid

2.1.2. Unpaid

2.1.3. P&S Intelligence database

2.2. Primary Research

2.3. Market Size Estimation

2.4. Data Triangulation

2.5. Currency Conversion Rates

2.6. Assumptions for the Study

2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Voice of Industry Experts/KOLs

Chapter 5. Market Indicators

Chapter 6. Industry Outlook

6.1. Market Dynamics

6.1.1. Trends

6.1.2. Drivers

6.1.3. Restraints/challenges

6.1.4. Impact analysis of drivers/restraints

6.2. Impact of COVID-19

6.3. Porter’s Five Forces Analysis

6.3.1. Bargaining power of buyers

6.3.2. Bargaining power of suppliers

6.3.3. Threat of new entrants

6.3.4. Intensity of rivalry

6.3.5. Threat of substitutes

Chapter 7. Global Market

7.1. Overview

7.2. Market Revenue, by Type (2017–2030)

7.3. Market Revenue, by Vector Type (2017–2030)

7.3.1. Viral-vector gene therapy market revenue, by type (2017–2030)

7.4. Market Revenue, by Application (2017–2030)

7.5. Market Revenue, by End User (2017–2030)

7.6. Market Revenue, by Region (2017–2030)

Chapter 8. North America Market

8.1. Overview

8.2. Market Revenue, by Type (2017–2030)

8.3. Market Revenue, by Vector Type (2017–2030)

8.3.1. Viral-vector gene therapy market revenue, by type (2017–2030)

8.4. Market Revenue, by Application (2017–2030)

8.5. Market Revenue, by End User (2017–2030)

8.6. Market Revenue, by Country (2017–2030)

Chapter 9. Europe Market

9.1. Overview

9.2. Market Revenue, by Type (2017–2030)

9.3. Market Revenue, by Vector Type (2017–2030)

9.3.1. Viral-vector gene therapy market revenue, by type (2017–2030)

9.4. Market Revenue, by Application (2017–2030)

9.5. Market Revenue, by End User (2017–2030)

9.6. Market Revenue, by Country (2017–2030)

Chapter 10. APAC Market

10.1. Overview

10.2. Market Revenue, by Type (2017–2030)

10.3. Market Revenue, by Vector Type (2017–2030)

10.3.1. Viral-vector gene therapy market revenue, by type (2017–2030)

10.4. Market Revenue, by Application (2017–2030)

10.5. Market Revenue, by End User (2017–2030)

10.6. Market Revenue, by Country (2017–2030)

Chapter 11. LATAM Market

11.1. Overview

11.2. Market Revenue, by Type (2017–2030)

11.3. Market Revenue, by Vector Type (2017–2030)

11.3.1. Viral-vector gene therapy market revenue, by type (2017–2030)

11.4. Market Revenue, by Application (2017–2030)

11.5. Market Revenue, by End User (2017–2030)

11.6. Market Revenue, by Country (2017–2030)

Chapter 12. MEA Market

12.1. Overview

12.2. Market Revenue, by Type (2017–2030)

12.3. Market Revenue, by Vector Type (2017–2030)

12.3.1. Viral-vector gene therapy market revenue, by type (2017–2030)

12.4. Market Revenue, by Application (2017–2030)

12.5. Market Revenue, by End User (2017–2030)

12.6. Market Revenue, by Country (2017–2030)

Chapter 13. Competitive Landscape

13.1. List of Market Players and Their Offerings

13.2. Competitive Benchmarking of Key Players

13.3. Product Benchmarking of Key Players

13.4. Recent Strategic Developments

Chapter 14. Company Profiles

14.1. Biogen Inc.

14.1.1. Business overview

14.1.2. Product and service offerings

14.1.3. Key financial summary

14.2. Sarepta Therapeutics Inc.

14.2.1. Business overview

14.2.2. Product and service offerings

14.2.3. Key financial summary

14.3. Gilead Sciences Inc.

14.3.1. Business overview

14.3.2. Product and service offerings

14.3.3. Key financial summary

14.4. Amgen Inc.

14.4.1. Business overview

14.4.2. Product and service offerings

14.4.3. Key financial summary

14.5. Novartis AG

14.5.1. Business overview

14.5.2. Product and service offerings

14.5.3. Key financial summary

14.6. Orchard Therapeutics plc

14.6.1. Business overview

14.6.2. Product and service offerings

14.6.3. Key financial summary

14.7. AGC Inc.

14.7.1. Business overview

14.7.2. Product and service offerings

14.7.3. Key financial summary

14.8. bluebird bio Inc.

14.8.1. Business overview

14.8.2. Product and service offerings

14.8.3. Key financial summary

14.9. Dynavax Technologies Corporation

14.9.1. Business overview

14.9.2. Product and service offerings

14.9.3. Key financial summary

14.10. AnGes Inc.

14.10.1. Business overview

14.10.2. Product and service offerings

14.10.3. Key financial summary

14.11. Lonza Group Ltd.

14.11.1. Business overview

14.11.2. Product and service offerings

14.11.3. Key financial summary

14.12. BioMarin Pharmaceutical Inc.

14.12.1. Business overview

14.12.2. Product and service offerings

14.12.3. Key financial summary

14.13. American Gene Technologies Inc.

14.13.1. Business overview

14.13.2. Product and service offerings

14.14. Astellas Pharma Inc.

14.14.1. Business overview

14.14.2. Product and service offerings

14.14.3. Key financial summary

14.15. Cellectis S.A.

14.15.1. Business overview

14.15.2. Product and service offerings

14.15.3. Key financial summary

Chapter 15. Appendix

15.1. Abbreviations

15.2. Sources and References

15.3. Related Reports

 

LIST OF TABLES

TABLE 1 ANALYSIS PERIOD OF THE STUDY

TABLE 2 DRIVERS FOR THE MARKET: IMPACT ANALYSIS

TABLE 3 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS

TABLE 4 GLOBAL GENE THERAPY MARKET, BY TYPE, $M (2017–2022)

TABLE 5 GLOBAL GENE THERAPY MARKET, BY TYPE, $M (2023–2026)

TABLE 6 GLOBAL GENE THERAPY MARKET, BY TYPE, $M (2027–2030)

TABLE 7 GLOBAL GENE THERAPY MARKET, BY VECTOR TYPE, $M (2017–2022)

TABLE 8 GLOBAL GENE THERAPY MARKET, BY VECTOR TYPE, $M (2023–2026)

TABLE 9 GLOBAL GENE THERAPY MARKET, BY VECTOR TYPE, $M (2027–2030)

TABLE 10 GLOBAL VIRAL-VECTOR GENE THERAPY MARKET, BY TYPE, $M (2017–2022)

TABLE 11 GLOBAL VIRAL-VECTOR GENE THERAPY MARKET, BY TYPE, $M (2023–2026)

TABLE 12 GLOBAL VIRAL-VECTOR GENE THERAPY MARKET, BY TYPE, $M (2027–2030)

TABLE 13 GLOBAL GENE THERAPY MARKET, BY APPLICATION, $M (2017–2022)

TABLE 14 GLOBAL GENE THERAPY MARKET, BY APPLICATION, $M (2023–2026)

TABLE 15 GLOBAL GENE THERAPY MARKET, BY APPLICATION, $M (2027–2030)

TABLE 16 GLOBAL GENE THERAPY MARKET, BY END USER, $M (2017–2022)

TABLE 17 GLOBAL GENE THERAPY MARKET, BY END USER, $M (2023–2026)

TABLE 18 GLOBAL GENE THERAPY MARKET, BY END USER, $M (2027–2030)

TABLE 19 GLOBAL GENE THERAPY MARKET, BY REGION, $M (2017–2022)

TABLE 20 GLOBAL GENE THERAPY MARKET, BY REGION, $M (2023–2026)

TABLE 21 GLOBAL GENE THERAPY MARKET, BY REGION, $M (2027–2030)

TABLE 22 NORTH AMERICA GENE THERAPY MARKET, BY TYPE, $M (2017–2022)

TABLE 23 NORTH AMERICA GENE THERAPY MARKET, BY TYPE, $M (2023–2026)

TABLE 24 NORTH AMERICA GENE THERAPY MARKET, BY TYPE, $M (2027–2030)

TABLE 25 NORTH AMERICA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2017–2022)

TABLE 26 NORTH AMERICA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2023–2026)

TABLE 27 NORTH AMERICA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2027–2030)

TABLE 28 NORTH AMERICA VIRAL-VECTOR GENE THERAPY MARKET, BY TYPE, $M (2017–2022)

TABLE 29 NORTH AMERICA VIRAL-VECTOR GENE THERAPY MARKET, BY TYPE, $M (2023–2026)

TABLE 30 NORTH AMERICA VIRAL-VECTOR GENE THERAPY MARKET, BY TYPE, $M (2027–2030)

TABLE 31 NORTH AMERICA GENE THERAPY MARKET, BY APPLICATION, $M (2017–2022)

TABLE 32 NORTH AMERICA GENE THERAPY MARKET, BY APPLICATION, $M (2023–2026)

TABLE 33 NORTH AMERICA GENE THERAPY MARKET, BY APPLICATION, $M (2027–2030)

TABLE 34 NORTH AMERICA GENE THERAPY MARKET, BY END USER, $M (2017–2022)

TABLE 35 NORTH AMERICA GENE THERAPY MARKET, BY END USER, $M (2023–2026)

TABLE 36 NORTH AMERICA GENE THERAPY MARKET, BY END USER, $M (2027–2030)

TABLE 37 NORTH AMERICA GENE THERAPY MARKET, BY COUNTRY, $M (2017–2022)

TABLE 38 NORTH AMERICA GENE THERAPY MARKET, BY COUNTRY, $M (2023–2026)

TABLE 39 NORTH AMERICA GENE THERAPY MARKET, BY COUNTRY, $M (2027–2030)

TABLE 40 EUROPE GENE THERAPY MARKET, BY TYPE, $M (2017–2022)

TABLE 41 EUROPE GENE THERAPY MARKET, BY TYPE, $M (2023–2026)

TABLE 42 EUROPE GENE THERAPY MARKET, BY TYPE, $M (2027–2030)

TABLE 43 EUROPE GENE THERAPY MARKET, BY VECTOR TYPE, $M (2017–2022)

TABLE 44 EUROPE GENE THERAPY MARKET, BY VECTOR TYPE, $M (2023–2026)

TABLE 45 EUROPE GENE THERAPY MARKET, BY VECTOR TYPE, $M (2027–2030)

TABLE 46 EUROPE VIRAL-VECTOR GENE THERAPY MARKET, BY TYPE, $M (2017–2022)

TABLE 47 EUROPE VIRAL-VECTOR GENE THERAPY MARKET, BY TYPE, $M (2023–2026)

TABLE 48 EUROPE VIRAL-VECTOR GENE THERAPY MARKET, BY TYPE, $M (2027–2030)

TABLE 49 EUROPE GENE THERAPY MARKET, BY APPLICATION, $M (2017–2022)

TABLE 50 EUROPE GENE THERAPY MARKET, BY APPLICATION, $M (2023–2026)

TABLE 51 EUROPE GENE THERAPY MARKET, BY APPLICATION, $M (2027–2030)

TABLE 52 EUROPE GENE THERAPY MARKET, BY END USER, $M (2017–2022)

TABLE 53 EUROPE GENE THERAPY MARKET, BY END USER, $M (2023–2026)

TABLE 54 EUROPE GENE THERAPY MARKET, BY END USER, $M (2027–2030)

TABLE 55 EUROPE GENE THERAPY MARKET, BY COUNTRY, $M (2017–2022)

TABLE 56 EUROPE GENE THERAPY MARKET, BY COUNTRY, $M (2023–2026)

TABLE 57 EUROPE GENE THERAPY MARKET, BY COUNTRY, $M (2027–2030)

TABLE 58 APAC GENE THERAPY MARKET, BY TYPE, $M (2017–2022)

TABLE 59 APAC GENE THERAPY MARKET, BY TYPE, $M (2023–2026)

TABLE 60 APAC GENE THERAPY MARKET, BY TYPE, $M (2027–2030)

TABLE 61 APAC GENE THERAPY MARKET, BY VECTOR TYPE, $M (2017–2022)

TABLE 62 APAC GENE THERAPY MARKET, BY VECTOR TYPE, $M (2023–2026)

TABLE 63 APAC GENE THERAPY MARKET, BY VECTOR TYPE, $M (2027–2030)

TABLE 64 APAC VIRAL-VECTOR GENE THERAPY MARKET, BY TYPE, $M (2017–2022)

TABLE 65 APAC VIRAL-VECTOR GENE THERAPY MARKET, BY TYPE, $M (2023–2026)

TABLE 66 APAC VIRAL-VECTOR GENE THERAPY MARKET, BY TYPE, $M (2027–2030)

TABLE 67 APAC GENE THERAPY MARKET, BY APPLICATION, $M (2017–2022)

TABLE 68 APAC GENE THERAPY MARKET, BY APPLICATION, $M (2023–2026)

TABLE 69 APAC GENE THERAPY MARKET, BY APPLICATION, $M (2027–2030)

TABLE 70 APAC GENE THERAPY MARKET, BY END USER, $M (2017–2022)

TABLE 71 APAC GENE THERAPY MARKET, BY END USER, $M (2023–2026)

TABLE 72 APAC GENE THERAPY MARKET, BY END USER, $M (2027–2030)

TABLE 73 APAC GENE THERAPY MARKET, BY COUNTRY, $M (2017–2022)

TABLE 74 APAC GENE THERAPY MARKET, BY COUNTRY, $M (2023–2026)

TABLE 75 APAC GENE THERAPY MARKET, BY COUNTRY, $M (2027–2030)

TABLE 76 LATAM GENE THERAPY MARKET, BY TYPE, $M (2017–2022)

TABLE 77 LATAM GENE THERAPY MARKET, BY TYPE, $M (2023–2026)

TABLE 78 LATAM GENE THERAPY MARKET, BY TYPE, $M (2027–2030)

TABLE 79 LATAM GENE THERAPY MARKET, BY VECTOR TYPE, $M (2017–2022)

TABLE 80 LATAM GENE THERAPY MARKET, BY VECTOR TYPE, $M (2023–2026)

TABLE 81 LATAM GENE THERAPY MARKET, BY VECTOR TYPE, $M (2027–2030)

TABLE 82 LATAM VIRAL-VECTOR GENE THERAPY MARKET, BY TYPE, $M (2017–2022)

TABLE 83 LATAM VIRAL-VECTOR GENE THERAPY MARKET, BY TYPE, $M (2023–2026)

TABLE 84 LATAM VIRAL-VECTOR GENE THERAPY MARKET, BY TYPE, $M (2027–2030)

TABLE 85 LATAM GENE THERAPY MARKET, BY APPLICATION, $M (2017–2022)

TABLE 86 LATAM GENE THERAPY MARKET, BY APPLICATION, $M (2023–2026)

TABLE 87 LATAM GENE THERAPY MARKET, BY APPLICATION, $M (2027–2030)

TABLE 88 LATAM GENE THERAPY MARKET, BY END USER, $M (2017–2022)

TABLE 89 LATAM GENE THERAPY MARKET, BY END USER, $M (2023–2026)

TABLE 90 LATAM GENE THERAPY MARKET, BY END USER, $M (2027–2030)

TABLE 91 LATAM GENE THERAPY MARKET, BY COUNTRY, $M (2017–2022)

TABLE 92 LATAM GENE THERAPY MARKET, BY COUNTRY, $M (2023–2026)

TABLE 93 LATAM GENE THERAPY MARKET, BY COUNTRY, $M (2027–2030)

TABLE 94 MEA GENE THERAPY MARKET, BY TYPE, $M (2017–2022)

TABLE 95 MEA GENE THERAPY MARKET, BY TYPE, $M (2023–2026)

TABLE 96 MEA GENE THERAPY MARKET, BY TYPE, $M (2027–2030)

TABLE 97 MEA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2017–2022)

TABLE 98 MEA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2023–2026)

TABLE 99 MEA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2027–2030)

TABLE 100 MEA VIRAL-VECTOR GENE THERAPY MARKET, BY TYPE, $M (2017–2022)

TABLE 101 MEA VIRAL-VECTOR GENE THERAPY MARKET, BY TYPE, $M (2023–2026)

TABLE 102 MEA VIRAL-VECTOR GENE THERAPY MARKET, BY TYPE, $M (2027–2030)

TABLE 103 MEA GENE THERAPY MARKET, BY APPLICATION, $M (2017–2022)

TABLE 104 MEA GENE THERAPY MARKET, BY APPLICATION, $M (2023–2026)

TABLE 105 MEA GENE THERAPY MARKET, BY APPLICATION, $M (2027–2030)

TABLE 106 MEA GENE THERAPY MARKET, BY END USER, $M (2017–2022)

TABLE 107 MEA GENE THERAPY MARKET, BY END USER, $M (2023–2026)

TABLE 108 MEA GENE THERAPY MARKET, BY END USER, $M (2027–2030)

TABLE 109 MEA GENE THERAPY MARKET, BY COUNTRY, $M (2017–2022)

TABLE 110 MEA GENE THERAPY MARKET, BY COUNTRY, $M (2023–2026)

TABLE 111 MEA GENE THERAPY MARKET, BY COUNTRY, $M (2027–2030)

TABLE 112 BIOGEN INC. – AT A GLANCE

TABLE 113 BIOGEN INC. – KEY FINANCIAL SUMMARY

TABLE 114 SAREPTA THERAPEUTICS INC. – AT A GLANCE

TABLE 115 SAREPTA THERAPEUTICS INC. – KEY FINANCIAL SUMMARY

TABLE 116 GILEAD SCIENCES INC. – AT A GLANCE

TABLE 117 GILEAD SCIENCES INC. – KEY FINANCIAL SUMMARY

TABLE 118 AMGEN INC. – AT A GLANCE

TABLE 119 AMGEN INC. – KEY FINANCIAL SUMMARY

TABLE 120 NOVARTIS AG – AT A GLANCE

TABLE 121 NOVARTIS AG – KEY FINANCIAL SUMMARY

TABLE 122 ORCHARD THERAPEUTICS PLC – AT A GLANCE

TABLE 123 ORCHARD THERAPEUTICS PLC – KEY FINANCIAL SUMMARY

TABLE 124 AGC INC. – AT A GLANCE

TABLE 125 AGC INC. – KEY FINANCIAL SUMMARY

TABLE 126 BLUEBIRD BIO INC. – AT A GLANCE

TABLE 127 BLUEBIRD BIO INC. – KEY FINANCIAL SUMMARY

TABLE 128 DYNAVAX TECHNOLOGIES CORPORATION – AT A GLANCE

TABLE 129 DYNAVAX TECHNOLOGIES CORPORATION – KEY FINANCIAL SUMMARY

TABLE 130 ANGES INC. – AT A GLANCE

TABLE 131 ANGES INC. – KEY FINANCIAL SUMMARY

TABLE 132 LONZA GROUP LTD. – AT A GLANCE

TABLE 133 LONZA GROUP LTD. – KEY FINANCIAL SUMMARY

TABLE 134 BIOMARIN PHARMACEUTICAL INC. – AT A GLANCE

TABLE 135 BIOMARIN PHARMACEUTICAL INC. – KEY FINANCIAL SUMMARY

TABLE 136 AMERICAN GENE TECHNOLOGIES INC. – AT A GLANCE

TABLE 137 ASTELLAS PHARMA INC. – AT A GLANCE

TABLE 138 ASTELLAS PHARMA INC. – KEY FINANCIAL SUMMARY

TABLE 139 CELLECTIS S.A. – AT A GLANCE

TABLE 140 CELLECTIS S.A. – KEY FINANCIAL SUMMARY

 

LIST OF FIGURES

FIG 1 MARKET SIZE BREAKDOWN BY SEGMENT

FIG 2 RESEARCH METHODOLOGY

FIG 3 BREAKDOWN OF PRIMARY RESEARCH, BY REGION

FIG 4 BREAKDOWN OF PRIMARY RESEARCH, BY DESIGNATION

FIG 5 BREAKDOWN OF PRIMARY RESEARCH, BY COMPANY TYPE

FIG 6 DATA TRIANGULATION APPROACH

FIG 7 CURRENCY CONVERSION RATES FOR USD (2022)

FIG 8 GLOBAL GENE THERAPY MARKET SUMMARY

FIG 9 BARGAINING POWER OF BUYERS

FIG 10 BARGAINING POWER OF SUPPLIERS

FIG 11 THREAT OF NEW ENTRANTS

FIG 12 INTENSITY OF RIVALRY

FIG 13 THREAT OF SUBSTITUTES

FIG 14 GLOBAL GENE THERAPY MARKET SNAPSHOT

FIG 15 GLOBAL GENE THERAPY MARKET, BY TYPE, $M (2017–2030)

FIG 16 GLOBAL GENE THERAPY MARKET, BY VECTOR TYPE, $M (2017–2030)

FIG 17 GLOBAL GENE THERAPY MARKET, BY APPLICATION, $M (2017–2030)

FIG 18 GLOBAL GENE THERAPY MARKET, BY END USER, $M (2017–2030)

FIG 19 MAJOR WORLDWIDE MARKETS FOR GENE THERAPY, $M

FIG 20 NORTH AMERICA GENE THERAPY MARKET SNAPSHOT

FIG 21 NORTH AMERICA GENE THERAPY MARKET, BY TYPE, $M (2017–2030)

FIG 22 NORTH AMERICA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2017–2030)

FIG 23 NORTH AMERICA GENE THERAPY MARKET, BY APPLICATION, $M (2017–2030)

FIG 24 NORTH AMERICA GENE THERAPY MARKET, BY END USER, $M (2017–2030)

FIG 25 NORTH AMERICA GENE THERAPY MARKET, BY COUNTRY, $M (2017–2030)

FIG 26 EUROPE GENE THERAPY MARKET SNAPSHOT

FIG 27 EUROPE GENE THERAPY MARKET, BY TYPE, $M (2017–2030)

FIG 28 EUROPE GENE THERAPY MARKET, BY VECTOR TYPE, $M (2017–2030)

FIG 29 EUROPE GENE THERAPY MARKET, BY APPLICATION, $M (2017–2030)

FIG 30 EUROPE GENE THERAPY MARKET, BY END USER, $M (2017–2030)

FIG 31 EUROPE GENE THERAPY MARKET, BY COUNTRY, $M (2017–2030)

FIG 32 APAC GENE THERAPY MARKET SNAPSHOT

FIG 33 APAC GENE THERAPY MARKET, BY TYPE, $M (2017–2030)

FIG 34 APAC GENE THERAPY MARKET, BY VECTOR TYPE, $M (2017–2030)

FIG 35 APAC GENE THERAPY MARKET, BY APPLICATION, $M (2017–2030)

FIG 36 APAC GENE THERAPY MARKET, BY END USER, $M (2017–2030)

FIG 37 APAC GENE THERAPY MARKET, BY COUNTRY, $M (2017–2030)

FIG 38 LATAM GENE THERAPY MARKET SNAPSHOT

FIG 39 LATAM GENE THERAPY MARKET, BY TYPE, $M (2017–2030)

FIG 40 LATAM GENE THERAPY MARKET, BY VECTOR TYPE, $M (2017–2030)

FIG 41 LATAM GENE THERAPY MARKET, BY APPLICATION, $M (2017–2030)

FIG 42 LATAM GENE THERAPY MARKET, BY END USER, $M (2017–2030)

FIG 43 LATAM GENE THERAPY MARKET, BY COUNTRY, $M (2017–2030)

FIG 44 MEA GENE THERAPY MARKET SNAPSHOT

FIG 45 MEA GENE THERAPY MARKET, BY TYPE, $M (2017–2030)

FIG 46 MEA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2017–2030)

FIG 47 MEA GENE THERAPY MARKET, BY APPLICATION, $M (2017–2030)

FIG 48 MEA GENE THERAPY MARKET, BY END USER, $M (2017–2030)

FIG 49 MEA GENE THERAPY MARKET, BY COUNTRY, $M (2017–2030)

FIG 50 BIOGEN INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)

FIG 51 SAREPTA THERAPEUTICS INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)

FIG 52 GILEAD SCIENCES INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)

FIG 53 AMGEN INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)

FIG 54 NOVARTIS AG – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)

FIG 55 ORCHARD THERAPEUTICS PLC – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)

FIG 56 AGC INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)

FIG 57 BLUEBIRD BIO INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)

FIG 58 DYNAVAX TECHNOLOGIES CORPORATION – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)

FIG 59 ANGES INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)

FIG 60 LONZA GROUP LTD. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)

FIG 61 BIOMARIN PHARMACEUTICAL INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)

FIG 62 ASTELLAS PHARMA INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)

FIG 63 CELLECTIS S.A. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)